ScholarIQanswers from OpenAlex & ORCID
Elena Élez
ResearcherPublications, citations & collaboration network
Elena Élez is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Elena Élez have?
ScholarIQindexed works
Elena Élez has 582 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Elena Élez have?
ScholarIQcitation count
Elena Élez has 20,209 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Elena Élez?
ScholarIQh-index
Elena Élez has an h-index of 58 in OpenAlex.
What is the i10-index of Elena Élez?
ScholarIQi10-index
Elena Élez has an i10-index of 160 in OpenAlex.
What is the ORCID of Elena Élez?
ScholarIQorcid
The ORCID for Elena Élez is on the source record.
What is the OpenAlex record for Elena Élez?
ScholarIQopenalex
The OpenAlex for Elena Élez is on the source record.
What are the most-cited papers on Elena Élez?
ScholarIQmost cited works
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W. Prager, Julien Taı̈eb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Élez, Felipe Melo Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Pápai, Pierre-Guillaume Poureau, Gábor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik Paul Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loïck Vidot, Josep Tabernero
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han